BioNTech SE CEO Sells Shares Under Trading Plan

BioNTech SE is now listed on the Nasdaq exchange. CEO and 10% owner Ugur Sahin sold 34,000 ordinary shares on October 1 and October 2, 2026. The sales consisted of two lots of 17,000 shares each, executed at prices of $97.46 and $96.72 per share, totaling approximately $3.30 million. The transactions were carried out under a Rule 10b5-1 trading plan established on June 3, 2026, and Sahin retained 180,209 shares following the sales.

The sales represent a meaningful reduction in Sahin's direct stake, which was 15.9% of his holding prior to the trades. The use of a pre-set trading plan provides context for the sales, suggesting they were planned trims of direct exposure rather than signals of immediate company concerns.